Latest Breaking News On - Division of lymphoma - Page 2 : comparemela.com

ASH Abstracts Showcase Effective Treatments for MM, CLL, FL

Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).

United statesRocky mountainSan diegoLucio gordanTanya siddiqiIanw flinnLucion gordanTycelj phillipsDavidj andorskyGilles sallesDivision of lymphomaDepartment of hematology hematopoietic cell transplantationFlorida cancer specialists research instituteAmerican society of hematologyMountain cancer centersEuropean medicines agency

Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL

Tycel Phillips, MD, discusses the rationale for launching the phase 3 GLOBRYTE trial evaluating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma, highlighting ongoing enrollment efforts.

United kingdomUnited statesSouth koreaTycel phillipsDivision of lymphomaDepartment of hematology hematopoietic cell transplantationHematopoietic cell transplantationMantle cell lymphomaCity of hopeOnclive tv

Allogene Therapeutics (ALLO) Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3

Allogene Therapeutics (ALLO) Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesMorgan conferenceAlex herreraDavid changZachary robertsDepartment of hematology hematopoietic cell transplantationAllogene therapeutics incResearch developmentDivision of lymphomaAllogene therapeuticsChief executive officerConsolidation trialLargeb cell lymphomaForesight diagnosticsHigher bar

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry s First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry s First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South san franciscoUnited statesSan franciscoCemacabtagene ansegedleucel cemaAlex herreraPolatuzumab vedotinChristine cassianoDavid changZachary robertsDivision of lymphomaCorporate affairs brand strategyAllogene therapeutics incDepartment of hematology hematopoietic cell transplantationCompany to focus manufacturing in cell forgeDrug administrationResearch development

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite s Tecartus® in Patients With Aggressive Blood Cancers

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite s Tecartus® in Patients With Aggressive Blood Cancers
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesFoster cityAndre goySwetha kambhampatiFrank neumannSanta monicaEvandro bezerraGilead sciences incHackensack university medical centerOhio state university comprehensive cancer centerLymphoma divisionGilead company nasdaqGilead companyMarrow transplant researchDivision of lymphomaProduct service